

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application

Listing of Claims

1. (Currently Amended) An isolated polypeptide selected from the group consisting of:
 - (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 19,
 - (b) a polypeptide comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 19, wherein said polypeptide has nucleic acid binding activity and
 - (c) ~~a polypeptide fragment comprising~~ an immunogenic fragment of a polypeptide having the amino acid sequence of SEQ ID NO: 19, wherein said fragment comprises at least 30 contiguous amino acids of SEQ ID NO: 19.
2. (Previously presented) An isolated polypeptide of claim 1, having the amino acid sequence of SEQ ID NO: 19.
- 3.-7. (Cancelled)
8. (Previously presented) A method for producing a polypeptide of claim 1, the method comprising:
 - (a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a polynucleotide encoding the polypeptide of claim 1, and
 - (b) recovering the polypeptide so expressed.
- 9.-14. (Cancelled)
15. (Currently Amended) A composition comprising ~~an effective amount of a~~ polypeptide of claim 1 and a pharmaceutically acceptable excipient.

16.-27. (Cancelled)

28. (Currently Amended) A method for screening a compound for effectiveness as an agonist of the polypeptide of claim 1, said method comprising:

- (a) exposing a sample comprising the polypeptide of claim 1 to a compound; and
- (b) detecting the presence of [[any]] agonist activity of the polypeptide of claim 1 in said sample.

29. (Withdrawn) A method for screening a compound for effectiveness as an antagonist of the polypeptide of claim 1, said method comprising:

- (a) exposing a sample comprising the polypeptide of claim 1 to a compound;
- (b) detecting the presence of any antagonist activity in said sample.

30. (New) A composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient, wherein administration of said compound results in the treatment or prevention of a cell proliferative disorder.